Clinical Trial

RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
RESET-MG: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Participants with Generalized Myasthenia Gravis
Protocol Amendment History 3 changes
critical Enrollment reopened 2026-08-14
notable Enrollment increased: 12 -> 24 participants 2026-08-14
minor Trial arms changed: 1 -> 2 2026-08-14
Trial Details
NCT Number NCT06359041
Lead Sponsor Cabaletta Bio
Conditions Generalized Myasthenia Gravis (gMG)
Enrollment 24 participants
Start Date 2024-12-17
Primary Completion 2029-09 (estimated)
Study Completion 2029-09 (estimated)
Updated on ClinicalTrials.gov 2026-08-13